iPSC-derived Rejuvenated T-cell Therapy for Extranodal NK/T-cell Lymphoma, Nasal Type

抄録

　Extranodal natural killer (NK)/ T-cell lymphoma, nasal type (ENKL), is an aggressive lymphoma that rapidly disseminates to various sites, resulting in a very poor prognosis. Antigen-specific cytotoxic T lymphocyte (CTL) therapy to target and kill tumor cells induces durable remissions in selected malignancies such as melanomas. As ENKL is invariably infected by Epstein-Barr virus (EBV), this lymphoma is a good target of CTL therapy. However, for most tumors, clinical utility is limited because CTL are continuously exposed to viral or tumor antigens and become exhausted. Exploiting fully rejuvenated induced pluripotent stem cell (iPSC)-derived antigen-specific CTL would be a powerful approach. After we reported the robust antitumor effect and survival advantage of rejuvenated CTL against EBV-infected tumor, we started a preclinical study utilizing this novel immunotherapy to EBV-associated lymphoma. We believe that iPSC-derived rejuvenated CTL therapy targeting EBV will provide a promising salvage therapy for ENKL.